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The Krebs cycle is of fundamental importance for the generation of the energetic and molecular needs of both prokaryotic and eukary-
otic cells. Both enantiomers of metabolite 2-hydroxyglutarate are directly linked to this pivotal biochemical pathway and are found
elevated not only in several cancers, but also in different variants of the neurometabolic disease 2-hydroxyglutaric aciduria. Recently
we showed that cancer-associated IDH2 germline mutations cause one variant of 2-hydroxyglutaric aciduria. Complementary to these
findings, we now report recessive mutations in SLC25A1, the mitochondrial citrate carrier, in 12 out of 12 individuals with combined
D-2- and L-2-hydroxyglutaric aciduria. Impaired mitochondrial citrate efflux, demonstrated by stable isotope labeling experiments and
the absence of SLC25A1 in fibroblasts harboring certain mutations, suggest that SLC25A1 deficiency is pathogenic. Our results identify
defects in SLC25A1 as a cause of combined D-2- and L-2-hydroxyglutaric aciduria.D-2-hydroxyglutarate (D-2-HG) and L-2-hydroxyglutarate
(L-2-HG) are associated with the Krebs (tricarboxylic acid/
citrate) cycle,1 with rare disorders,2 and with certain types
of cancer.3–5 D-2-hydroxyglutaric aciduria (D-2-HGA),
characterized by elevated levels of D-2-HG, is either auto-
somal recessive, resulting from mutations in D2HGDH6
(type I [MIM 600721]), or is caused by recurrent usually
de novo dominant gain-of-function mutations in IDH27
(type II [MIM 613657]). Manifestations of both types of
D-2-HGA include developmental delay, hypotonia, and
seizures.2 Recessive mutations in L2HGDH result in L-2-
hydroxyglutaric aciduria8,9 (L-2-HGA [MIM 236792]), and
predominant signs include macrocephaly, developmental
delay, epilepsy, and cerebellar ataxia. Combined D-2- and
L-2-hydroxyglutaric aciduria (D,L-2-HGA), characterized
by elevated levels of both D-2-HG and L-2-HG in body
fluids, is not caused by mutations in any of the above-
mentioned genes andmainlymanifests in a severeneonatal
epileptic encephalopathy, absence of developmental prog-
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The AmElevated D-2-HG levels are also found in gliomas and
myeloid leukemias3,11 and are associated with recurrent
mutations in the isocitrate dehydrogenase (IDH) genes
IDH1 or IDH2. These mutations disable the normal ability
of IDH to convert isocitrate to a-ketoglutarate and result in
a new function: converting a-ketoglutarate to D-2-HG.3
However, elevated D-2-HG and L-2-HG levels are also
found in thyroid carcinomas without IDH mutations,4
caused by still unknown mechanisms. The exact role of
‘‘oncometabolite’’ 2-hydroxyglutarate (2-HG) in cancer is
not yet fully understood, but recent studies indicate an
important role in epigenetics.12–14 Identifying the genetic
cause of combined D,L-2-HGA could therefore not only
improve our knowledge of the pathophysiology of this
neurometabolic disorder, but also provide further insight
into its role in cancer.
We performed whole-exome sequencing to identify the
genetic basis of combined D,L-2-HGA in DNA of three
affected individuals and the unaffected parents of one of
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Table 1. Homozygous or Compound Heterozygous SLC25A1
Mutations Found in Combined D,L-2-HGA Cases
Subject
Nucleotide
Change Deduced Effect Exon
SIFT
Scorea
1b c.578C>G p.Ser193Trp 6 0.00
2b c.844C>G p.Arg282Gly 9 0.00




5 c.18_24dup p.Ala9Profs*82 1 –
c.499G>A p.Gly167Arg 5 0.00
6 c.18_24dup p.Ala9Profs*82 1 –
c.134C>T p.Pro45Leu 2 0.00
7b c.18_24dup p.Ala9Profs*82 1 –
c.768C>G p.Tyr256* 8 –
8b c.430G>C p.Glu144Gln 4 0.00
9 c.18_24dup p.Ala9Profs*82 1 –
10b c.605T>C p.Met202Thr 6 0.01








The primers used for PCR amplification and sequencing are summarized in
Table S3. SLC25A1 RefSeq NM_005984.2.
aAll missense mutations were predicted with SIFT to be damaging (p < 0.05).
bHomozygosity or compound heterozygosity was confirmed by DNA
sequencing of the parents.
cHomozygous mutation was also found with DNA sequencing in affected
sibling.
dMutation was confirmed in mRNA isolated from fibroblasts.diagnosed with combined D,L-2-HGA from 12 unrelated
families (Arabic, European, or Latin-American descent)
were included in this study. They all showed elevated levels
of D-2-HG and L-2-HG in urine (Table S2). Written consent
was obtained from participants and/or their guardians for
the exome sequencing analysis; for all other participants
informed consent was waived because of the retrospective
nature of the study. The study received Institutional
Review Board approval from the VU University Medical
Center Amsterdam (registered with the US Office of Hu-
man Research Protections under number IORG0002436).
Genomic DNA was extracted from blood, and 3 mg was
fragmented via Covaris technology. Fragments were
ligated with adaptors (Illumina), amplified by ligation-
mediated PCR, and enriched with SureSelect Human All
Exon v.2 Kit (Agilent). Sequencing was performed on a
HiSeq2000 (Illumina) and generated paired-end 100 bp
reads. Mapping of the reads to the human reference
genome (UCSC Genome Browser hg19) was done with
Burrows-Wheeler Aligner.15 VarScan16 software was used
for calling SNPs and indels. Annotation of the obtained628 The American Journal of Human Genetics 92, 627–631, April 4, 2variants was performed with ANNOVAR.17 We obtained a
mean coverage depth of the exomes ranging from 833 to
1093 and searched for nonsynonymous single-nucleotide
variants (SNVs) in the family of subject 1, not present in
dbSNP (132) or 1000 Genomes, and with a SIFT18 predic-
tion score < 0.05. Assuming a model in which mutations
have a recessive effect,10 we identified nonsynonymous
SNVs in three genes (OR52K1, OR51I2, and SLC25A1 [Re-
fSeq accession number NM_005984.2, MIM 190315])
that were homozygous (100% of the reads) in the affected
individual and heterozygous (50% of the reads) in either
parent with >403 coverage depth. Of these three genes,
only SNVs in SLC25A1, with the above-mentioned criteria,
were identified in the other two affected individuals (sub-
jects 2 and 3). A similar search for small insertions or dele-
tions did not identify any additional genes. Sanger
sequencing of the ORF of SLC25A1 confirmed the muta-
tions in these three individuals and their families and re-
vealed mutations in nine additional unrelated affected
subjects (Table 1). In total, 12 different mutations were
detected (Figure 1A): eight missense, one nonsense, two
frameshift (of which one was recurrent in four unrelated
individuals), and onemutation resulting in a splicing error.
The latter mutation, c.821C>T, found in three unrelated
individuals, is located at the most 30 end of exon 8 and
introduces a splice donor site, resulting in a deletion in
mRNA (r.820_821del), and is predicted to cause a frame-
shift at the protein level (p.Ala274Ilefs*24). Sequencing
of mRNA from fibroblasts derived from subject 4 con-
firmed a 2 bp deletion (Figure S2). All missense mutations
were predicted with SIFT to be damaging (Table 1).
With immunoblot analysis, we examined SLC25A1 in fi-
broblasts available from seven affected individuals (Figures
1B and S3). SLC25A1 was detected in cells from control
subjects and all subjects harboring homozygous or com-
pound heterozygous missense mutations. However, in
cells from subjects containing two alleles with truncating
mutations (subjects 7 and 9), no protein was detected,
probably as a consequence of nonsense-mediated decay.
The homozygous splice site mutation c.821C>T (subject
4; p.Ala274Ilefs*24) had reduced levels of SLC25A1. This
could be explained by some authentic spliced protein
product (p.Ala274Val), or alternatively, because the frame-
shift occurs at the C-terminal end, this protein could still
be immunodetected but is degraded at higher rate.
The location of SLC25A1within the human genome was
previously described to be involved in other disorders.19
SLC25A1 is located on chromosome 22q11 within the crit-
ical region deleted in DiGeorge syndrome20 (MIM 188400).
DiGeorge syndrome is a rather common congenital disor-
der (prevalence of 1:4,000) caused by a hemizygous dele-
tion of chromosome 22q11.2 (containing ~45 genes),
with a wide variety of clinical abnormalities including
heart defects, velopharyngeal inadequacies, recurrent
infections, and learning disabilities.21 Consequently,
individuals with DiGeorge syndrome are heterozygous
carriers of SLC25A1 deficiency.013
Figure 1. Schematic Overview of Genomic
Organization and Protein Domain Struc-
ture of SLC25A1
(A) SLC25A1 contains nine exons that
encode a 311 amino acid long product.
The first 13 amino acids are a transit peptide
(red) for mitochondrial targeting, and the
mature protein contains six membrane-
spanning helices (orange). Locations of
the 12 different identified mutations are
shown. An alignment of the involved
amino acids with different species is shown
in Figure S1.
(B) Immunoblot analysis of SLC25A1 accu-
mulation in fibroblasts derived from con-
trol ‘‘C’’ and affected subjects 1–5, 7,
and 9. SLC25A1 is immunodetected in
control, subjects 1–3 (homozygous mis-
sense mutations), and subject 5 with muta-
tion c.18_24dup (p.Ala9Profs*82) and
c.499G>A (p.Gly167Arg). Low detection
in subject 4 (homozygous mutation
c.821C>T [p.Ala274Ilefs*24]) and no detec-
tion in subject 7 with mutation c.18_24dup
(p.Ala9Profs*82) and c.768C>G (p.Tyr256*)
and subject 9 (homozygous mutation
c.18_24dup [p.Ala9Profs*82]) is consistent
with the presence of truncating mutations.
The whole-blot image and a blot with a
lower exposure time are shown in Figure S3.Expression of SLC25A1 mRNA is high in liver, kidney,
and pancreas.22 It encodes a protein of 311 amino acids
containing six transmembrane helices that is located in
the inner mitochondrial membrane. SLC25A1 mediates
the efflux ofmitochondrial citrate or isocitrate in exchange
for cytosolic malate.23 Citrate and isocitrate are intermedi-
ates of the Krebs cycle, which occurs in the matrix of mito-
chondria and is responsible for energy production. Citrate
exported by SLC25A1 out of the mitochondria into the
cytosol is converted into acetyl coenzyme A (acetyl-CoA),
which is essential for fatty acid and sterol synthesis.24
Furthermore, cytosolic citrate is an important regulator
of glycolysis, because it is an allosteric inhibitor of 6-phos-
phofructokinase (PFK1), the most important regulator
enzyme of glycolysis.24
To examine the effect of SLC25A1 deficiency, we retro-
spectively measured the urinary citrate and isocitrate levels
of individuals with combined D,L-2-HGA by using liquid
chromatography-tandem mass spectrometry. Compared
to age-matched controls (n¼ 40), significantly lower levels
of both metabolites were detected (Figures 2A and 2B;
Table S2). Interestingly, the eldest affected individual (sub-
ject 10) in our cohort showed the highest levels of citrate
and isocitrate (Table S2). To further study SLC25A1 activity,
we incubated combined D,L-2-HGA-affected fibroblasts
(n ¼ 7) and controls (n ¼ 2) with [U-13C6]glucose-enriched
medium. [U-13C6]glucose is metabolized via glycolysis and
enters the Krebs cycle predominantly as [13C2]acetyl-CoA.
The condensation reaction of [13C2]acetyl-CoA and oxalo-
acetate results in intramitochondrial [13C2]citrate. In com-
bined D,L-2-HGA-affected fibroblasts, we detected lowerThe Am[13C2]citrate levels in the culture medium than in controls
(Figure 2C; Table S2). This demonstrates that SLC25A1
mutations result in impaired citrate efflux. Interestingly,
fibroblasts from subject 7 (c.18_24dup and c.768C>G)
and subject 9 (c.18_24dup) showed ~7% efflux as com-
pared to controls, indicating that citrate can leave to a
lesser extent the mitochondrial matrix via other means
than SLC25A1 or is formed in the cytosol.
Individuals with combined D,L-2-HGA excrete increased
levels of several Krebs cycle intermediates including
a-ketoglutarate, malate, fumarate, and succinate, accom-
panied with decreased levels of citrate and isocitrate (Table
S2). We speculate that the increased urinary excretion of
D-2-HG and L-2-HG is caused by the inability of mitochon-
dria to export citrate and isocitrate into the cytosol. This
would probably result in increased mitochondrial concen-
trations, and subsequently higher excretion, of Krebs cycle
metabolites downstream of isocitrate. We therefore
measured the above-mentioned metabolites in homoge-
nates of fibroblasts from controls and affected individuals
(Table S4). Compared to controls, the levels of D-2-HG
and L-2-HG in affected individuals are increased, which
is in agreement with previously reported data.25 Addition-
ally, citrate levels were lower in affected fibroblasts, but
isocitrate and the other metabolites were normal
compared to controls.
In conclusion, SLC25A1 mutations cause combined
D,L-2-HGA as well as altered levels of several Krebs cycle
intermediates. This finding provides the basis for an under-
standing of the pathophysiology and future therapeutic
research concerning this disease that may include citrateerican Journal of Human Genetics 92, 627–631, April 4, 2013 629
Figure 2. Decreased Citrate and Isocitrate Levels in Combined D,L-2-HGA
(A and B) Urinary levels of (A) citrate and (B) isocitrate were measured with LC-MS/MS in samples of controls (n¼ 40) and of individuals
with combined D,L-2-HGA (n ¼ 11) with SLC25A1 mutations. Horizontal lines indicate the group sample means. The differences
observed between controls and combined D,L-2-HGA-affected individuals were statistically significant by Mann-Whitney’s test for
both citrate (p¼ 0.0011) and isocitrate (p¼ 0.0015) levels (p< 0.05 was considered significant). Urinary levels of an unrelatedmetabolite
(a-aminoadipic acid) was not significantly different between individuals with combined D,L-2-HGA and controls (Figure S4).
(C) Fibroblast cultures derived from affected subjects (n ¼ 7) were given [U-13C6]glucose, which is metabolized by glycolysis predomi-
nantly to [13C2]acetyl-CoA. [
13C2]acetyl-CoA is converted to [
13C2]citrate withinmitochondria via the Krebs cycle. Levels of [
13C2]citrate
were measured after 72 hr incubation in culture medium and are expressed as percentage compared to control fibroblasts (n ¼ 2). Error
bars indicate standard error of mean of replicate measurements (n ¼ 3).supplementation. SLC25A1 deficiency may be underdiag-
nosed and inclusion in the differential diagnosis of mito-
chondrial disorders should be considered. Further research
is needed to unravel how SLC25A1 defects cause elevation
of 2-HG, a cancer-associated metabolite. Although no can-
cer was diagnosed in our combined D,L-2HGA cohort
(Table S1), an important role for citrate or SLC25A1 has
previously been implied in epigenetics or cancer
biology.26–30 The absence of cancer cases in our combined
D,L-2-HGA cohort might be explained by the early age of
death. Another explanation might be that the L-2-HG
levels in our cohort are not as high as in L-2-HGA-affected
individuals. Only L-2-HGA has previously been associated
with higher incidences of cancer.5 In both types of D-2-
HGA, no higher incidence of cancer has been found.2
Moreover, certain cancer types show elevated levels of
2-HG but contain nomutations in IDH1 or IDH2.4 It would
therefore be interesting to further investigate the role of
citrate and SLC25A1 in these cancer types.Supplemental Data
Supplemental Data include four figures and four tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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